EMA Authorised: Osvyrti (denosumab) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Osvyrti, a denosumab product from Accord Healthcare S.L.U., for bone resorption disorders including osteoporosis and postmenopausal osteoporo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Osvyrti (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Accord Healthcare S.L.U.. Decision date: 17/12/2025